Drug intelligence / Profile preview

tezacitabine + oxaliplatin

Development stage: Unknown
Lead developer: Manufacturer
Modality: Small Molecules
Administration: Intravenous

Overview

Tezacitabine + oxaliplatin is an investigational combination therapy comprising tezacitabine, a nucleoside analog, and oxaliplatin, a platinum-based chemotherapeutic agent. Tezacitabine acts by inhibiting DNA synthesis through incorporation into DNA, leading to chain termination and apoptosis. Oxaliplatin forms DNA crosslinks primarily at guanine bases, causing DNA double-strand breaks and triggering apoptosis. This combination has been studied in clinical trials for the treatment of metastatic colorectal cancer, aiming to leverage the synergistic cytotoxic effects of both agents to improve antitumor efficacy[3][5].

Brand names: Eloxatin
Other names: Tezacitabine and oxaliplatinTezacitabine/oxaliplatin

Targets

DNA

Beyond the preview

Go deeper on tezacitabine + oxaliplatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tezacitabine + oxaliplatin.

Explore the full profile